Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Units: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;1,040;93;1,133;
%Companies according to biotechnology used: Genetic code;32;43;33;
%Companies according to biotechnology used: Functional units;40;51;41;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;22;41;24;
%Companies according to biotechnology used: Bioprocesses;48;69;50;
%Companies according to biotechnology used: Sub-cellular organisms;5;12;6;
%Companies according to biotechnology used: Bio-computing;24;28;24;
%Companies according to biotechnology used: Nanobiotechnology;13;13;13;
%Companies according to biotechnology used: Other;15;8;14;
Companies in which biotechnology activities are: Main and/or exclusive;581;22;603;
Companies in which biotechnology activities are: A secondary line of business;155;18;173;
Companies in which biotechnology activities are: A tool necessary for production;305;53;357;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45;49;45;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;19;3;18;
%Company by field(s) of ultimate application of biotechnology use: Food products;30;39;31;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23;17;22;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;17;14;
%Company by field(s) of ultimate application of biotechnology use: Industry;13;9;12;
Personnel in R&D in biotechnology (no. of persons);8,124;3,386;11,510;
Personnel in R&D in biotechnology (no. of persons): Researchers;4,552;1,650;6,202;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3,572;1,736;5,308;
Personnel in R&D in biotechnology (no. of persons): women;4,363;2,026;6,389;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2,368;935;3,304;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1,995;1,090;3,086;
Personnel in R&D in biotechnology (FTE);5,788.1;2,448.9;8,236.9;
Personnel in R&D in biotechnology (FTE): Researchers;3,364.3;1,231.9;4,596.1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2,423.8;1,217.0;3,640.8;
Personnel in R&D in biotechnology (FTE): women;3,197.5;1,501.0;4,698.5;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1,803.7;708.8;2,512.5;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1,393.8;792.2;2,186.0;
Internal expenditure on R&D (thousands of euros);558,184;211,247;769,431;
1) By nature of the expense: Current expenses;518,032;201,684;719,715;
1.1) Remuneration to researchers;154,555;66,892;221,447;
1.2) Remuneration to technicians and assistants;72,617;50,192;122,809;
1.3) Other current expenses;290,860;84,599;375,459;
2) By nature of the expense: Capital expenses;40,152;9,563;49,715;
2.1) Land and buildings;6,661;2,860;9,521;
2.2) Equipment and instruments;24,465;6,001;30,466;
2.3) Acquisition of specific R&D software;1,157;653;1,810;
2.4) Otros productos de propiedad intelectual específicos para I+D;7,869;49;7,919;
1.1) By origin of the funds: Own funds;385,847;105,066;490,913;
1.2) By origin of the funds: From companies;53,140;29,409;82,548;
1.3) By origin of the funds: Public Administration funds;64,168;32,641;96,809;
1.4) By origin of the funds: From Universities;197;0;197;
1.5) By origin of the funds: From non profit private institutions;588;4,177;4,766;
1.6) By origin of the funds: Foreign funds;54,244;39,954;94,197;
Purchase of R&D services in biotechnology (thousands of euros);68,331;51,951;120,281;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;22,667;46,897;69,564;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;45,664;5,054;50,718;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;47;23;45;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;13;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;15;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13;15;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;17;11;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;19;10;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16;13;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;29;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;53;39;52;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;14;20;
% Companies that have requested biotechnology patents in Biotechnology;15;17;15;
Number of patents requested;525;156;681;
% Companies with income of an international origin related to biotechnological activities;24.9;18.4;24.3;
% Turnover representing income of an international origin related to biotechnological activities;6.00;1.00;1.00;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;45.20;73.10;59.60;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;54.80;26.90;40.40;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;89.00;72.50;80.40;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;7.50;24.90;16.50;
% Income of an international origin related with activities according to the classification: Operating source abroad;2.20;2.30;2.20;
% Income of an international origin related with activities according to the classification: Other;1.40;0.40;0.90;
Notes:
1) '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Source: National Statistics Institute